Evidence map›Paper›PMID 26569093›Full record

ArticleBone marrow transplantation2016

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.

L Sellner, A Boumendil, H Finel, S Choquet, G de Rosa, F Falzetti, R Scime, G Kobbe, F Ferrara, A Delmer and 14 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07481669 (Autologous Stem Cell Transplantation With TEAM), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07481669 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Autologous Stem Cell Transplantation With TEAM (Thiotepa, Etoposide, Cytarabine, Melphalan) Conditioning for Lymphoma Patients With High Risk of Central Nervous System Relapse

TypeinterventionalSponsorSecond Affiliated Hospital, Zhejiang University, School of MedicineRan2026 to 2028Enrolled45ConditionsLymphoma Patients With High-risk of Central Nervous System RelapseArmsTEAM regimen (thiotepa, etoposide, cytarabine and melphalan)
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. A Retrospective Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphoma Patients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 17 institutions in 5 countries.

L SellnerDepartment of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
A BoumendilLymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France.
H FinelLymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France.
S ChoquetDepartment of Hematology, Pitié-Salpêtrière Hospital, Paris, France.
G de RosaUniversity of Napoli, Napoli, Italy.
F FalzettiUniversity of Perugia, Perugia, Italy.
R ScimeDepartment of Hematology, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
G KobbeUniversity Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
F FerraraCardarelli Hospital, Napoli, Italy.
A DelmerService d'Hématologie Clinique, Hôpital Robert Debré, Centre Hospitalier Universitaire (CHU) de Reims, Reims, France.
H SayerDepartment of Hematology and Oncology, Helios Hospital Erfurt, Erfurt, Germany.
S AmorimAPHP, Hopital Saint-louis, Hemato-Oncology Paris Diderot University, Sorbonne Paris Cité, Paris, France.
R BouabdallahHematology Department, Paoli Calmettes Institute, Marseille Aix-Marseille University, Marseille, France.
J FinkeDepartment of Hematology, Freiburg University Medical Center, Freiburg, Germany.
G SallesHematologie, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre Bénite, France.
I Yakoub-AghaLIRIC-U995, Hematology Department and Hematopoietic Stem Cell Transplantation Unit, University-Hospital of Lille, Lille, France.
E FaberDepartment of Hemato-Oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
E Nicolas-VirelizierHematology Department, Centre Leon Berard, Lyon, France.
L FacchiniHematology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy.
D VallisaHematology Unit, Ospedale Civile, Piacenza, Italy.
E ZuffaHematology Unit, S Maria delle Croci Hospital, Ravenna, Italy.
A SuredaLymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France.
P DregerDepartment of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
EBMT Lymphoma Working Party
European Society for Blood and Marrow Transplantation · FRAix-Marseille Université · FRCentre Hospitalier Universitaire de Reims · FRCentre Léon Bérard · FRDüsseldorf University Hospital · DEHeidelberg University · DEHelios Klinikum Erfurt · DEHospices Civils de Lyon · FRInstitut Català d'Oncologia · ESLille Inflammation Research International Center · FROspedale "Santa Maria delle Croci" di Ravenna · ITOspedale Vincenzo Cervello · ITPalacký University Olomouc · CZSorbonne Université · FRUniversité Paris Cité · FRUniversity Medical Center Freiburg · DEUniversity of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.

Indexed as

RegistriesStem Cell TransplantationAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAutograftsCarmustineCytarabineDisease-Free SurvivalFemaleHumansLymphomaMaleMelphalanMiddle AgedCarmustineCytarabineMelphalanPodophyllotoxinThiotepa

Identifiers

PMID26569093
OpenAlexW2179367818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.